<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523987</url>
  </required_header>
  <id_info>
    <org_study_id>PA02/07/18</org_study_id>
    <nct_id>NCT04523987</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.</brief_title>
  <official_title>A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to&#xD;
      standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic&#xD;
      PDAC patients. Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a&#xD;
      standard-of-care by their treating physician will be offered to participate in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral ciprofloxacin (study drug) will be administered twice a day throughout each 28-day cycle&#xD;
      of gemcitabine and nab-paclitaxel chemotherapy. The patient will start taking ciprofloxacin&#xD;
      from the evening of day 1 of chemotherapy and end on the morning of day 29 of each cycle.&#xD;
&#xD;
      Ciprofloxacin tablets should be taken in the morning and evening at about the same time each&#xD;
      day. Swallow the tablet whole. Do not split, crush or chew the tablet. Ciprofloxacin can be&#xD;
      taken with or without food&#xD;
&#xD;
      With each study visit, the physician will prescribe 1-month supply of oral ciprofloxacin to&#xD;
      be taken home and self-administered by the patient. The physician will have to indicate&#xD;
      &quot;pancreatic cancer microbiome study&quot; on the remarks column for each cycle oral ciprofloxacin&#xD;
      is ordered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic PDAC patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor Effect - Solid Tumors</measure>
    <time_frame>4 years</time_frame>
    <description>Patients are be re-evaluated for response every 8-12 weeks (±10 days), per standard-of-care.&#xD;
Response and progression will be evaluated in this study using the international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in RECIST.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>gemcitabine and nab-paclitaxel chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.</description>
    <arm_group_label>gemcitabine and nab-paclitaxel chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent. Written informed consent must be obtained prior to performing&#xD;
             any study-related procedures.&#xD;
&#xD;
          -  Age ≥ 21 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed, treatment-naïve, locally advanced or&#xD;
             metastatic pancreatic adenocarcinoma planned to commence on gemcitabine and&#xD;
             nab-paclitaxel chemotherapy.&#xD;
&#xD;
          -  Patient must have measurable disease as defined by the Response Evaluation Criteria in&#xD;
             Solid Tumors Version 1.1 (RECIST v 1.1 guidelines)&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  CrCl ≥ 30 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to ciprofloxacin or other quinolones&#xD;
&#xD;
          -  On tizanidine or theophylline and unable to stop these medication&#xD;
&#xD;
          -  Known QTc prolongation (QTc &gt;500 msec) or torsade de pointes&#xD;
&#xD;
          -  Presence of Clostridium difficile-associated diarrhea or colitis&#xD;
&#xD;
          -  Known history of myasthenia gravis&#xD;
&#xD;
          -  Known G6PD deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Ean Chee</last_name>
    <role>Principal Investigator</role>
    <affiliation>cheng_ean_chee@nuhs.edu.sg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Ean Chee</last_name>
    <phone>6779 5555</phone>
    <email>cheng_ean_chee@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Ean Chee</last_name>
      <phone>779 5555</phone>
      <email>cheng_ean_chee@nuhs.edu.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: A comprehensive topic review of literature. World J Gastroenterol. 2017 Mar 14;23(10):1899-1908. doi: 10.3748/wjg.v23.i10.1899. Review.</citation>
    <PMID>28348497</PMID>
  </results_reference>
  <results_reference>
    <citation>Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Paster BJ, Joshipura K, Wong DT. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012 Apr;61(4):582-8. doi: 10.1136/gutjnl-2011-300784. Epub 2011 Oct 12.</citation>
    <PMID>21994333</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Nab-Paclitaxel Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

